- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07688902
Intralesional Versus Perilesional 5% Dextrose Injection in Partial Rotator Cuff Tears
Comparison of Clinical and Ultrasonographic Outcomes of Intralesional and Perilesional 5% Dextrose Injection in Patients With Partial Rotator Cuff Tears: A Prospective Randomized Double-Blind Controlled Trial
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Rotator cuff tears are one of the leading causes of shoulder pain and functional limitation. Partial rotator cuff tears may become chronic and may not respond adequately to conventional conservative treatments such as activity modification, physical therapy, and nonsteroidal anti-inflammatory drugs.
Dextrose injection is a regenerative injection therapy that aims to stimulate tissue healing responses in chronic musculoskeletal disorders. It is thought to promote fibroblast activation, collagen synthesis, and proliferative healing processes in degenerative tendon, ligament, and enthesis lesions. Ultrasound guidance allows accurate and safe delivery of the injectate to the target tissue and enables objective follow-up of tendon morphology during the treatment process.
This study will include adult patients with partial rotator cuff tears diagnosed by clinical examination and imaging. Participants will be randomized into two groups using a computer-based random number system. The researcher performing the randomization will know the treatment allocation, while the participants and the physician assessing the clinical outcomes will be blinded to treatment groups.
Both groups will receive ultrasound-guided 5% dextrose injection to the supraspinatus enthesis. The intralesional group will additionally receive intralesional 5% dextrose injection, and the perilesional group will additionally receive perilesional 5% dextrose injection. Injections will be applied using the peppering technique, with 0.1-0.2 cc administered to each point. A total of three treatment sessions will be performed at 21-day intervals.
Clinical outcomes will include shoulder pain assessed by the Numeric Rating Scale, shoulder pain and disability assessed by the Shoulder Pain and Disability Index, and health-related quality of life assessed by the Short Form-12 Health Survey. Ultrasonographic outcomes will include supraspinatus tendon thickness and partial defect size. Clinical evaluations will be performed at baseline, 9 weeks, and 12 weeks after treatment. Ultrasonographic evaluations will be performed at baseline and 12 weeks.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Esra Ülgen Kıratlıoğlu, MD
- Telefonnummer: +905079614194
- E-mail: esraulgen@gmail.com
Studiesteder
-
-
-
Ankara, Tyrkiet (Türkiye)
- Rekruttering
- Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital
-
Kontakt:
- Esra Ülgen Kıratlıoğlu
- Telefonnummer: +905079614194
- E-mail: esraulgen@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Diagnosis of partial rotator cuff tear by a specialist physician after appropriate clinical examination and imaging evaluation
- Shoulder pain and functional limitation lasting for at least 3 months
- Clinically confirmed shoulder impingement findings, defined as at least one positive test among Neer, Hawkins-Kennedy, or painful arc tests
- Age between 18 and 75 years
- Ability to comply with the study procedures and attend follow-up visits regularly
- Willingness to participate in the study and provide written informed consent
Exclusion Criteria:
- Advanced cognitive impairment or dementia preventing reliable completion of questionnaires
- Refusal to participate in the study or inability to provide informed consent
- Full-thickness rotator cuff tear
- Major tendon pathology other than the supraspinatus tendon, such as full-thickness subscapularis tear or biceps tendon rupture
- Advanced acromioclavicular joint osteoarthritis, marked impingement, or marked adhesive capsulitis
- Advanced glenohumeral joint arthritis
- Active infection, cellulitis, or dermatologic lesion at the injection site
- Bleeding diathesis or anticoagulant use
- Known allergy or intolerance to dextrose injection
- Intra-articular shoulder injection, including steroid, platelet-rich plasma, or prolotherapy, within the last 3 months
- Previous shoulder surgery
- Uncontrolled diabetes mellitus, defined as HbA1c >8.5%, or severe endocrine or metabolic disorder
- Immunosuppression or active infection
- Rheumatologic shoulder involvement
- Neurological disease affecting shoulder movements
- Pregnancy
- Active malignancy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Intralesional 5% Dextrose Injection
Participants in this group will receive ultrasound-guided 5% dextrose injection to the supraspinatus enthesis.
In addition, intralesional 5% dextrose injection will be applied to the partial rotator cuff tear using the peppering technique.
Injections will be performed in three treatment sessions at 21-day intervals.
All participants will receive a home-based exercise program after completion of the injection treatments.
|
Ultrasound-guided 5% dextrose injection will be applied to the supraspinatus enthesis and additionally into the partial tear lesion using the peppering technique.
A volume of 0.1-0.2
cc will be administered to each point.
The treatment will consist of three sessions performed at 21-day intervals.
|
|
Aktiv komparator: Perilesional 5% Dextrose Injection
Participants in this group will receive ultrasound-guided 5% dextrose injection to the supraspinatus enthesis.
In addition, perilesional 5% dextrose injection will be applied around the partial rotator cuff tear using the peppering technique.
Injections will be performed in three treatment sessions at 21-day intervals.
All participants will receive a home-based exercise program after completion of the injection treatments.
|
Ultrasound-guided 5% dextrose injection will be applied to the supraspinatus enthesis and additionally around the partial tear lesion using the peppering technique.
A volume of 0.1-0.2
cc will be administered to each point.
The treatment will consist of three sessions performed at 21-day intervals.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Shoulder Pain Intensity Assessed by Numeric Rating Scale
Tidsramme: Baseline, 9 weeks, and 12 weeks after treatment
|
Shoulder pain intensity will be assessed using the Numeric Rating Scale.
Night pain, worst daytime shoulder pain, and average shoulder pain will be evaluated on a 0-10 scale, where 0 indicates no pain and 10 indicates the worst pain imaginable.
Higher scores indicate greater pain intensity.
|
Baseline, 9 weeks, and 12 weeks after treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability Index
Tidsramme: Baseline, 9 weeks, and 12 weeks after treatment
|
Shoulder pain and disability will be assessed using the Shoulder Pain and Disability Index.
The scale consists of 13 items in two domains: pain and disability.
Each item is scored from 0 to 10, and the total score is converted to a 0-100 scale.
Higher scores indicate greater pain and functional impairment.
|
Baseline, 9 weeks, and 12 weeks after treatment
|
|
Change in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey
Tidsramme: Baseline, 9 weeks, and 12 weeks after treatment
|
Health-related quality of life will be assessed using the Short Form-12 Health Survey.
The questionnaire includes 12 items and provides physical component summary and mental component summary scores.
Higher scores indicate better health-related quality of life.
|
Baseline, 9 weeks, and 12 weeks after treatment
|
|
Change in Supraspinatus Tendon Thickness Assessed by Ultrasonography
Tidsramme: Baseline and 12 weeks after treatment
|
Supraspinatus tendon thickness will be measured in millimeters using shoulder ultrasonography with a high-frequency linear probe in a standardized position.
|
Baseline and 12 weeks after treatment
|
|
Change in Partial Rotator Cuff Defect Size Assessed by Ultrasonography
Tidsramme: Baseline and 12 weeks after treatment
|
Partial rotator cuff defect size will be measured in millimeters using shoulder ultrasonography with a high-frequency linear probe in a standardized position.
|
Baseline and 12 weeks after treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: ESRA Ülgen Kıratlıoğlu, Ankara City Hospital Bilkent
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- E2-26-14590
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Rotator Cuff Tendinopati
-
Elite College of Management Sciences, Gujranwala...AfsluttetRotator Cuff Tendinopati | Rotator Cuff syndromPakistan
-
Rafeef Hassan AsiriAktiv, ikke rekrutterendeRotator Cuff senebetændelse | Rotator Cuff syndrom | Skuldersmerter syndromSaudi Arabien
-
Peking University Third HospitalIkke rekrutterer endnu
-
The Cleveland ClinicAktiv, ikke rekrutterendeRotator Cuff River | Rotator cuff reparationerForenede Stater
-
Ivan WongAfsluttetRotator cuff skade | Fuld tykkelse rotator manchet rive | Rotator Cuff syndrom | Lidelse af Rotator Cuff | Hudtransplantat (Allograft) (Autograft) FejlCanada
-
Parc de Salut MarHospital Clinic of Barcelona; Hospital Universitario Fundación Jiménez... og andre samarbejdspartnereAktiv, ikke rekrutterendeSkulder sygdom | Massive rotator manchet tårerSpanien
-
Arthrex, Inc.RekrutteringFuld tykkelse Rotator Cuff RivningForenede Stater
-
Rush University Medical CenterAfsluttetFuld tykkelse rotator manchet riveForenede Stater
-
St. Antonius HospitalAfsluttetLidelse af Rotator Cuff | Anden ustabilitet, skulder | Rotator Cuff læsionHolland
-
BAAT Medical Products B.V.Aktiv, ikke rekrutterende
Kliniske forsøg med Intralesional 5% Dextrose Injection
-
Instituto de Oftalmología Fundación Conde de ValencianaAfsluttet
-
Assiut UniversityIkke rekrutterer endnu
-
Beijing Anzhen HospitalRekrutteringMyokardieinfarktKina
-
Beijing Anzhen HospitalChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.Afsluttet
-
King Edward Medical UniversityIkke rekrutterer endnu
-
Montefiore Medical CenterAfsluttetHidradenitis SuppurativaForenede Stater
-
Columbia UniversityUniversity of MinnesotaAfsluttet
-
Maharajgunj Medical CampusAfsluttet
-
CSPC Ouyi Pharmaceutical Co., Ltd.UkendtAvanceret kræft i bugspytkirtlenKina
-
Luye Pharma Group Ltd.AfsluttetAvanceret solid tumorKina